Trellus Health (LSE:TRLS) has completed the conversion of approximately £65,000 in principal and accrued interest from its secured convertible loan notes into equity, issuing 16,804,593 new ordinary shares. The transaction finalises the conversion of the company’s first tranche of notes, with the new shares expected to commence trading on AIM around 25 February 2026.
Following admission, Trellus Health’s total issued share capital will increase to 208,719,361 ordinary shares, establishing a revised reference point for shareholder voting rights and disclosure obligations under UK market transparency regulations. The conversion simplifies the company’s capital structure and modestly lowers its debt position by removing the converted loan notes.
The updated voting rights total will allow investors to assess whether notification requirements apply to their holdings or any changes in ownership, improving clarity around significant shareholdings in the company.
Trellus Health’s outlook remains constrained by weak financial fundamentals, including substantial ongoing losses, negative free cash flow and declining equity levels, despite the benefit of operating without debt. Technical indicators provide a more positive signal, with strong price momentum above key moving averages, although valuation support remains limited given continued losses and the absence of a dividend yield.
More about Trellus Health PLC
Trellus Health plc is a healthcare technology company offering Trellus Elevate, a digital, value-based condition management platform that combines data analytics with personalised, resilience-focused care programmes for complex chronic diseases. The company initially targets gastrointestinal conditions such as inflammatory bowel disease and collaborates with pharmaceutical partners to support clinical trials and commercialisation through patient engagement and adherence solutions.
Leave a Reply